CAS 1036959-27-9

(2R)-Vildagliptin ((R)-1-[N-(3-Hydroxyadamantan-1-yl)glycyl]-2-pyrrolidinecarbonitrile)

CAS: 1036959-27-9

Heterocyclic compounds with nitrogen hetero-atom(s) only, excluding aromatic or modified aromatic

Formula: C₁₇H₂₅N₃O₂

Color and Shape: Off-White Powder

Molecular weight: 303.19468

Ref: 45-1A10340

(2R)-1-(2-((3-Hydroxyadamantan-1-yl)amino)acetyl)pyrrolidine-2-carbonitrile

CAS: 1036959-27-9

(2R)-1-(2-((3-Hydroxyadamantan-1-yl)amino)acetyl)pyrrolidine-2-carbonitrile

Purity: 99%

Molecular weight: 303.41g/mol

Ref: 54-OR1074846

(R)-Vildagliptin

CAS: 1036959-27-9

Formula: C₁₇H₂₅N₃O₂

Color and Shape: White To Off-White Solid

Molecular weight: 303.41

Ref: 4Z-V-228

(2R)-Vildagliptin

CAS: 1036959-27-9

Applications (2R)-Vildagliptin is an oral anti-hyperglycemic agent that inhibit dipeptidyl peptidase 4 (DPP-4) which can act as a serine exopeptidase. Aside from there use in type 2 diabetes, gliptins have positive cardiovascular and anti-inflammtatory effects. Antidiabetic.
References Ahren, B., et al.: J. Clin. Endocrinol. Metab., 89, 2078 (2004), Ahren, B., et al.: Diabetes Care, 27, 2874 (2004), Barlocco, D., et al.: Curr. Opin. Invest. Drugs, 5, 1094 (2004),

Formula: C₁₇H₂₅N₃O₂

Color and Shape: Off-White To Light Beige

Molecular weight: 303.40

Ref: TR-V305005

(R)-Vildagliptin

CAS: 1036959-27-9

Formula: C₁₇H₂₅N₃O₂

Molecular weight: 303.41

Ref: ST-EA-CP-V1013

(2R)-1-[2-[(3-Hydroxytricyclo[3.3.1.1(3,7)]dec-1-yl)amino]acetyl]-2-pyrrolidinecarbonitrile

CAS: 1036959-27-9

(2R)-1-[2-[(3-Hydroxytricyclo[3.3.1.1(3,7)]dec-1-yl)amino]acetyl]-2-pyrrolidinecarbonitrile is a drug that belongs to the class of DPP-IV inhibitors and is used for the treatment of type 2 diabetes mellitus. It has been shown to be effective in reducing postprandial blood glucose levels in patients with type 2 diabetes mellitus. The mechanism of action of this drug is not fully understood, but it may have an effect on insulin release from pancreatic beta cells and/or inhibition of gastric emptying or intestinal absorption of glucose. This drug has been shown to reduce tubulointerstitial injury in diabetic rats and can be used as a combination therapy for type 2 diabetes mellitus. There are no known clinically relevant interactions between (2R)-1-[2-[(3-Hydroxytricyclo

Formula: C₁₇H₂₅N₃O₂

Purity: Min. 95%

Molecular weight: 303.4 g/mol

Ref: 3D-FH46129